Title : Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.

Pub. Date : 2013 Nov

PMID : 23982118






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The exploratory pharmacokinetic/pharmacogenetic study showed that CYP2A6 variants (*4, *7, *9) are associated with a lower metabolic ratio of S-1 (exposure ratio of 5-fluorouracil to tegafur). Tegafur cytochrome P450 family 2 subfamily A member 6 Homo sapiens